open access

Vol 89, No 6 (2018)
Guidelines / Expert consensus
Published online: 2018-06-29
Get Citation

Standards of Polish Society of Gynecologists and Obstetricians in management of women with diabetes

Ewa Wender-Ożegowska, Dorota Bomba-Opoń, Jacek Brązert, Zbigniew Celewicz, Krzysztof Czajkowski, Paweł Gutaj, Aneta Malinowska-Polubiec, Agnieszka Zawiejska, Mirosław Wielgoś
DOI: 10.5603/GP.a2018.0059
Pubmed: 30010185
Ginekol Pol 2018;89(6):341-350.

open access

Vol 89, No 6 (2018)
Published online: 2018-06-29


Not available


Not available
Get Citation


recommendations; diabetes; pregnancy; pregestational diabetes; gestational diabetes

About this article

Standards of Polish Society of Gynecologists and Obstetricians in management of women with diabetes


Ginekologia Polska


Vol 89, No 6 (2018)

Article type

Guidelines / Expert consensus



Published online






Bibliographic record

Ginekol Pol 2018;89(6):341-350.


pregestational diabetes
gestational diabetes


Ewa Wender-Ożegowska
Dorota Bomba-Opoń
Jacek Brązert
Zbigniew Celewicz
Krzysztof Czajkowski
Paweł Gutaj
Aneta Malinowska-Polubiec
Agnieszka Zawiejska
Mirosław Wielgoś

References (47)
  1. Robinson A, Nwolise C, Shawe J. Contraception for women with diabetes: challenges and solutions. Open Access J Contracept. 2016; 7: 11–18.
  2. WHO. Medical eligibility criteria for contraceptive use Fifth edition 2015. Geneva: WHO 2015.
  3. Guerin A, Nisenbaum R, Ray JG. Use of maternal GHb concentration to estimate the risk of congenital anomalies in the offspring of women with prepregnancy diabetes. Diabetes Care. 2007; 30(7): 1920–1925.
  4. Jensen DM, Korsholm L, Ovesen P, et al. Peri-conceptional A1C and risk of serious adverse pregnancy outcome in 933 women with type 1 diabetes. Diabetes Care. 2009; 32(6): 1046–1048.
  5. Egan AM, McVicker L, Heerey A, et al. Diabetic retinopathy in pregnancy: a population-based study of women with pregestational diabetes. J Diabetes Res. 2015; 2015: 310239.
  6. Chew EY, Mills JL, Metzger BE, et al. Metabolic Control and Progression of Retinopathy: The Diabetes in Early Pregnancy Study. Diabetes Care. 1995; 18(5): 631–637.
  7. Piccoli GB, Tavassoli E, Melluzza C, et al. Severe diabetic nephropathy in type 1 diabetes and pregnancy--a case series. Rev Diabet Stud. 2013; 10(1): 68–78.
  8. Khoury JC, Miodovnik M, LeMasters G, et al. Pregnancy outcome and progression of diabetic nephropathy. What's next? J Matern Fetal Neonatal Med. 2002; 11(4): 238–244.
  9. Mathiesen ER, Ringholm L, Feldt-Rasmussen Bo, et al. Obstetric nephrology: pregnancy in women with diabetic nephropathy--the role of antihypertensive treatment. Clin J Am Soc Nephrol. 2012; 7(12): 2081–2088.
  10. Diabetology C. 2018 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clinical Diabetology. 2018; 7(1): 1–90.
  11. Kitzmiller JL, Block JM, Brown FM, et al. Managing preexisting diabetes for pregnancy: summary of evidence and consensus recommendations for care. Diabetes Care. 2008; 31(5): 1060–1079.
  12. Wytyczne ESC dotyczące postępowania w chorobach sercowo-naczyniowych u kobiet w ciąży Kardiologia Polska. 2011; 69: 341–400.
  13. Sowinski J, Czupryniak L, Milewicz A, et al. Recommendations of the Polish Society of Endocrinology and Polish Diabetes Association for the management of thyroid dysfunction in type 1 and type 2 diabetes. Endokrynol Pol. 2013; 64(1): 73-77.
  14. Hubalewska-Dydejczyk A, Lewiński A, Milewicz A, et al. [Management of thyroid diseases during pregnancy]. Endokrynol Pol. 2011; 62(4): 362–381.
  15. Bomba-Opoń D, Hirnle L, Kalinka J, et al. Folate supplementation during the preconception period, pregnancy and puerperium. Polish Society of Gynecologists and Obstetricians Guidelines. Ginekol Pol. 2017; 88(11): 633–636.
  16. Płudowski P, Karczmarewicz E, Bayer M, et al. Practical guidelines for the supplementation of vitamin D and the treatment of deficits in Central Europe — recommended vitamin D intakes in the general population and groups at risk of vitamin D deficiency. Endokrynologia Polska. 2013; 64(4): 319–327.
  17. Bullo M, Tschumi S, Bucher BS, et al. Pregnancy outcome following exposure to angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists: a systematic review. Hypertension. 2012; 60(2): 444–450.
  18. Taguchi N, Rubin ET, Hosokawa A, et al. Prenatal exposure to HMG-CoA reductase inhibitors: effects on fetal and neonatal outcomes. Reprod Toxicol. 2008; 26(2): 175–177.
  19. Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. BMJ. 2015; 350: h1035–h1035.
  20. Kitzmiller JL, Buchanan TA, Siri K, et al. Pre-Conception Care of Diabetes, Congenital Malformations, and Spontaneous Abortions. Diabetes Care. 1996; 19(5): 514–541.
  21. Ray JG, O'Brien TE, Chan WS. Preconception care and the risk of congenital anomalies in the offspring of women with diabetes mellitus: a meta-analysis. QJM. 2001; 94(8): 435–444.
  22. Parretti E, Mecacci F, Papini M, et al. Third-Trimester Maternal Glucose Levels From Diurnal Profiles in Nondiabetic Pregnancies: Correlation with sonographic parameters of fetal growth. Diabetes Care. 2001; 24(8): 1319–1323.
  23. Mosca A, Paleari R, Dalfrà MG, et al. Reference intervals for hemoglobin A1c in pregnant women: data from an Italian multicenter study. Clin Chem. 2006; 52(6): 1138–1143.
  24. Jovanovic L, Knopp RH, Kim H, et al. Elevated Pregnancy Losses at High and Low Extremes of Maternal Glucose in Early Normal and Diabetic Pregnancy: Evidence for a protective adaptation in diabetes. Diabetes Care. 2005; 28(5): 1113–1117.
  25. Lambert K, Holt RIG. The use of insulin analogues in pregnancy. Diabetes Obes Metab. 2013; 15(10): 888–900.
  26. Farrar D, Tuffnell DJ, West J, et al. Continuous subcutaneous insulin infusion versus multiple daily injections of insulin for pregnant women with diabetes. Cochrane Database Syst Rev. 2016(6): CD005542.
  27. Wender-Ozegowska E, Zawiejska A, Ozegowska K, et al. Multiple daily injections of insulin versus continuous subcutaneous insulin infusion for pregnant women with type 1 diabetes. Aust N Z J Obstet Gynaecol. 2013; 53(2): 130–135.
  28. Murphy HR, Rayman G, Lewis K, et al. Effectiveness of continuous glucose monitoring in pregnant women with diabetes: randomised clinical trial. BMJ. 2008; 337: a1680.
  29. Yogev Y, Ben-Haroush A, Chen R, et al. Continuous glucose monitoring for treatment adjustment in diabetic pregnancies-a pilot study. Diabetic Medicine. 2003; 20(7): 558–562.
  30. IOM. Weight Gain During Pregnancy: Reexamining the Guidelines. Washington (DC): National Academies Press (US); Epub 2010/07/30. 2009.
  31. Rizzo TA, Dooley SL, Metzger BE, et al. Prenatal and perinatal influences on long-term psychomotor development in offspring of diabetic mothers. Am J Obstet Gynecol. 1995; 173(6): 1753–1758.
  32. Nielsen LR, Müller C, Damm P, et al. Reduced prevalence of early preterm delivery in women with Type 1 diabetes and microalbuminuria--possible effect of early antihypertensive treatment during pregnancy. Diabet Med. 2006; 23(4): 426–431.
  33. Carr DB, Koontz GL, Gardella C, et al. Diabetic nephropathy in pregnancy: suboptimal hypertensive control associated with preterm delivery. Am J Hypertens. 2006; 19(5): 513–519.
  34. Abalos E, Duley L, Steyn DW, et al. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev. 2007(1): CD002252.
  35. Lausman A, Kingdom J. MATERNAL FETAL MEDICINE COMMITTEE. Intrauterine growth restriction: screening, diagnosis, and management. J Obstet Gynaecol Can. 2013; 35(8): 741–748.
  36. ACOG Committee on Practice Bulletins--Obstetrics. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. Obstet Gynecol. 2002; 99(1): 159–167.
  37. RCOG. Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. .
  38. WHO. WHO recommendations for prevention and treatment of pre-eclampsia and eclampsia. 2011.
  39. Rozporządzenie Ministra Zdrowia z dnia 9 listopada 2015 r. w sprawie standardów postępowania medycznego przy udzielaniu świadczeń zdrowotnych w dziedzinie położnictwa i ginekologii z zakresu okołoporodowej opieki położniczo-ginekologicznej, sprawowanej nad kobietą w okresie ciąży, porodu, połogu, w przypadkach występowania określonych powikłań oraz opieki nad kobietą w sytuacji niepowodzeń położniczych. 2015.
  40. Diabetes Care. 2017; 40(Suppl 1): S114–S119.
  41. Metzger BE, Gabbe SG, Persson B, et al. International Association of Diabetes and Pregnancy Study Groups Consensus Panel. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care. 2010; 33(3): 676–682.
  42. NICE. Diabetes in Pregnancy: Management of Diabetes and Its Complications from Preconception to the Postnatal Period. .
  43. Escobar-Morreale HF, Roldán-Martín MB. Type 1 Diabetes and Polycystic Ovary Syndrome: Systematic Review and Meta-analysis. Diabetes Care. 2016; 39(4): 639–648.
  44. Polish Gynecological Society – Ultrasound Section Guidelines on ultrasound screening in uncomplicated pregnancy – 2015. 2015; 86(7): 551–558.
  45. Gutaj P, Wender-Ozegowska E. Diagnosis and Management of IUGR in Pregnancy Complicated by Type 1 Diabetes Mellitus. Curr Diab Rep. 2016; 16(5): 39.
  46. Bomba-Opoń D, Drews K, Huras H, et al. Polish Gynecological Society Recommendations for Labor Induction. Ginekol Pol. 2017; 88(4): 224–234.
  47. Glueck CJ, Salehi M, Sieve L, et al. Growth, motor, and social development in breast- and formula-fed infants of metformin-treated women with polycystic ovary syndrome. J Pediatr. 2006; 148(5): 628–632.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: